The vaccine against the coronavirus jointly developed by the University of Oxford and the British-Swedish pharmaceutical company AstraZeneca will arrive in Brazil in January 2021, and not this December, as previously planned. The Minister of Health of the country Eduard Pazwell announced this in an interview with CNN Brasil on Friday.
“Oxford vaccine shipments will begin in January. The first batch of 30 million [doses] will arrive in January. Then the pharmaceutical raw materials for the production of 70 million doses in Brazil,” the minister said. According to the official, the corresponding postponement is stipulated by the contract between the government and AstraZeneca. It was previously expected that the first 15 million doses would arrive in the South American republic in December.
According to the TV channel, the company has asked the Brazilian authorities to postpone the delivery due to “increased demand for an effective drug against coronavirus worldwide.” At the same time, AstraZeneca is considering Brazil as one of the priority areas for the distribution of its vaccine, according to CNN Brasil.
On Thursday, the Globo TV channel reported that the Brazilian National Sanitary Inspection Agency (Anvisa) received an application from a pharmaceutical manufacturer to register a vaccine against coronavirus in the largest South American state. It was noted that its consideration will take place according to a simplified procedure.
At the end of June, the Brazilian Ministry of Health agreed on a joint study and localization in the country of the production of a vaccine against coronavirus, which is being developed by scientists from the British University of Oxford and AstraZeneca. Then it was reported that the cost of the initial investment in the purchase of drugs and production equipment will amount to $127 million. 10,000 volunteers are taking part in trials of this vaccine in Brazil.
In addition to this drug, the country is testing vaccines from the Chinese Sinovac Biotec, the German Biotech, the American Pfizer, and the Janssen-Cilag company, the pharmaceutical division of the international company Johnson & Johnson.